Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rohto Pharmaceutical Co., Ltd.
Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
SARS-CoV-2 infection is confirmed on antigen test or PCR test
Pulmonary infiltrative shadow is confirmed on chest X-ray test
Mechanical ventilation is being utilized, or Acute Respiratory Failure whose PaO2 is not being achieved to 80 mmHg in spite of High-flow oxygen therapy
You may not be if
Continue treatment for Pneumonia before SARS-CoV-2 infection
